NOI - Oxford Nanopore PromethION Flow Cells and cD
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to award a Firm-Fixed-Price purchase order on a non-competitive basis to Oxford Nanopore Technologies Inc. for PromethION flow cells and cDNA-PCR sequencing kits. This acquisition supports the National Institute on Aging's (NIA) Center for Alzheimer's Disease and Related Dementias (CARD) long-read RNA sequencing project on ROSMAP brain samples. Responses from interested parties are due by June 8, 2026, at 9:00 AM EDT.
Scope of Work
The requirement is for proprietary items essential for CARD's existing PromethION 48 sequencing infrastructure. Oxford Nanopore Technologies Inc. is the sole manufacturer of these components. Key Requirements:
- Oxford Nanopore PromethION Flow Cells Packs DNA (Catalogue Number: FLO-PRO114M, Quantity: 72)
- Must generate consensus data at a modal accuracy above 99%.
- Compatible with Nanopore PromethION 48 sequencers and CARD's existing infrastructure/bioinformatics pipelines.
- Oxford Nanopore cDNA-PCR Sequencing Kit V14 (Catalogue Number: SQK-LSK114-XL, Quantity: 48)
- Must prepare cDNA for nanopore sequencing, requiring no more than 10 ng poly(A)+ RNA or 500 ng total RNA as starting material.
- Provides for 6 reactions.
- Compatible with R10.4.1 nanopore chemistry.
- Enables direct comparison with previously generated long-read WGS data.
Contract & Timeline
- Type: Firm-Fixed-Price purchase order (non-competitive Notice of Intent).
- Duration: 6 months from the date of award.
- Set-Aside: Not set aside for small business.
- NAICS Code: 325413 – In-Vitro Diagnostic Substance Manufacturing (Small Business Size Standard: 1,250 employees).
- Response Due: June 8, 2026, at 9:00 AM EDT.
- Published: May 29, 2026.
Submission & Evaluation
This is a combined synopsis/solicitation issued as a Notice of Intent (NOI) for a non-competitive award. The NIH intends to award to Oxford Nanopore Technologies Inc. as the sole manufacturer of the required proprietary components.
- Submission Method: Electronically to nicholas.capobianco@nih.gov.
- Required Information: Unit price, list price, shipping/handling, delivery timeframe, F.O.B. point, product/catalog numbers, product descriptions, UEI, TIN, and business size certification. Offerors must be registered in SAM.gov.
- Evaluation Factors: While this is an NOI, potential evaluation factors for competitive offers may include past performance, technical capability, special features, and lifecycle considerations.
Additional Notes
This acquisition is conducted under FAR 12.603 and 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii), and is not expected to exceed the simplified acquisition threshold. Invoices must be uploaded to IPP (https://www.ipp.gov).